Last reviewed · How we verify

Enalapril/hydrochlorothiazide — Competitive Intelligence Brief

Enalapril/hydrochlorothiazide (Enalapril/hydrochlorothiazide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor / thiazide diuretic combination. Area: Cardiovascular.

marketed ACE inhibitor / thiazide diuretic combination Angiotensin-converting enzyme (ACE); sodium-chloride cotransporter Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Enalapril/hydrochlorothiazide (Enalapril/hydrochlorothiazide) — Erasmus Medical Center. Enalapril inhibits angiotensin-converting enzyme (ACE) to reduce angiotensin II production, while hydrochlorothiazide acts as a thiazide diuretic to promote sodium and water excretion, together lowering blood pressure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Enalapril/hydrochlorothiazide TARGET Enalapril/hydrochlorothiazide Erasmus Medical Center marketed ACE inhibitor / thiazide diuretic combination Angiotensin-converting enzyme (ACE); sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor / thiazide diuretic combination class)

  1. Erasmus Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Enalapril/hydrochlorothiazide — Competitive Intelligence Brief. https://druglandscape.com/ci/enalapril-hydrochlorothiazide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: